Samsung Biologics workers partially strike
Around 400 union members have begun a partial strike scheduled to last until 27 November.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
Around 400 employees of Samsung Biologics in South Korea began a partial strike on Friday. The union and management have yet to reach agreement on pay and other employment conditions.
The strike is scheduled to run from 6 to 27 November inclusive. It is a partial work stoppage, meaning not all employees and processes will be halted. The scale of the impact on production has therefore not yet been established.
The union and Samsung Biologics have been negotiating for some time. Earlier talks broke down after mediation failed to produce an agreement. According to South Korean reports, the union had previously also taken action in which employees refused overtime and work on public holidays.
A court has previously designated nine production processes that are subject to a strike ban. These include cell culture, bioreactors, harvesting, filtration and the filling of active pharmaceutical ingredients. According to reports, the strike may not affect those processes.
Samsung Biologics produces medicines on behalf of other pharmaceutical companies. A prolonged or broader strike could therefore become relevant to customers that procure production capacity outside their own factories. The start of the partial strike does not indicate whether deliveries are being disrupted.
The strike is primarily about an employment dispute, not a new medicine or a safety incident. The coming weeks will show whether the limited action accelerates negotiations and whether the protected production processes are sufficient to maintain contractual deliveries.
Also show the region and a close-up
Both sides of the figures
▲ Bright spots
- The strike is partial and does not cover all production processes.
- According to reports, nine production processes have been excluded from the right to strike by a court.
▼ Concerns
- Negotiations over pay and employment conditions have broken down again.
- A longer action could create uncertainty for pharmaceutical customers that outsource production.
Critical note
No source has yet reported production losses or delivery problems. Its commercial impact therefore cannot yet be inferred from the start of the strike.
Who notices what
- Workers
- Around 400 union members are temporarily stopping work to put pressure on the negotiations.
- Businesses
- Samsung Biologics and its pharmaceutical customers mainly face uncertainty if the action becomes broader or lasts longer.
- Government
- The court's demarcation of protected processes determines how much scope the strike has.
Every point comes from the article’s sources and was included in the fact check.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The strike and the protected production processes have been described in several open sources. Claims about possible effects on deliveries are expressed conditionally.
Editor's note
The start of the strike, its scale and its planned duration have been reported by several South Korean sources. There is no confirmation yet of production or delivery damage.Sources
- Samsung Biologics workers launch partial strike — Aju Press
- Samsung Biologics union begins three-week partial strike — Health Chosun
- Samsung Biologics talks collapse again as union plans second strike — Seoul Economic Daily
More on this in Dutch media
- de Volkskrant — „samsung biologics”
- NU.nl — „samsung biologics”
- De Telegraaf — „samsung biologics”